Laxxon Medical Names Lauren Chung PhD MBA as Chief Financial Officer
NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Laxxon Medical Corp., a leading pharma technology platform company focusing on oral drug...
top of page
Laxxon Medical
Oct 143 min read
Laxxon Medical to Present Innovative Oral GLP-1 Agonist including Multi-Compartment Micro-Tablet Form at 2024 BIO-Europe Convention, Aiming to Enhance Compliance for Special Patient Groups
Laxxon is seeking out-licensing opportunities for lead asset LXM.2, or co-developments projects with 3DSP platform technology SPID® at...
Laxxon Medical
Oct 92 min read
Laxxon Medical to Attend CPHI Milan 2024, Showcasing the cGMP Printing Technology at Adare Pharma Solution’s Facility in Pessano, Italy
NEW YORK, NY / ACCESSWIRE / October 9, 2024 / Laxxon Medical , a US-based pharma-technology company pioneering a new generation of...
Laxxon Medical
Oct 23 min read
Laxxon Medical and Adare Pharma Solutions Announce Joint Cooperation for Production of cGMP 3D Printed Oral Dosage Forms in Europe and US
The cooperation between Laxxon and Adare enables the clinical and commercial production of advanced drug delivery systems at Adare’s cGMP fa
Laxxon Medical
May 222 min read
Laxxon Medical Announces Development Program for Non-Invasive, 3D Printed Oral GLP-1 Asset, Offering an Alternative to GLP-1 Injections on Market
Learn more about Laxxon Medical's groundbreaking 3D printed oral GLP-1 asset, offering an alternative to injections in obesity treatments.
Laxxon Medical
May 206 min read
Investing in Safety: Laxxon Medical's QR Code Technology and the Fight Against Counterfeit Drugs
Counterfeit medicine is a threat to public health. Technologies like 3D printing and QR codes help protect both patients and drug integrity.
Laxxon Medical
May 162 min read
Laxxon Medical to Showcase LXM.2, a Novel 3D Printed GLP-1 Agonist at BIO 2024
Laxxon Medical announced its participation in the 2024 BIO International Convention, to showcase its LXM.2 asset to potential partners.
Laxxon Medical
May 133 min read
LXM.2 A 3D printed oral GLP-1 Agonist for weight loss
LXM.2 is Laxxon Medical’s oral GLP-1 Agonist treatment for weight loss, offering patients a non-invasive, once-a-day treatment made...
Laxxon Medical
May 65 min read
Understanding GLP-1 Medications for Diabetes and Obesity
Learn all about GLP-1 medications for diabetes and obesity, including benefits, side effects, and how they work.
Laxxon Medical
Apr 293 min read
The Controlled Release Drug Delivery Market
Explore the future of drug delivery, Laxxon Medical's innovative 3D technology, and how controlled-release drugs are reshaping healthcare.
bottom of page